文献速递慢阻肺

COPD成人出院后长效吸入药物无意停药的人群队列研究

Medication Discontinuation in Adults With COPD Discharged From the Hospital: A Population-Based Cohort Study.
PubMed 文献 · Chest · 2020-10-02

基于加拿大安大略省2004至2016年健康行政数据的回顾性队列研究,纳入连续取药≥1年的≥66岁COPD成人,评估出院后长效吸入药物无意停药风险。住院者停用LAMA和LABA-ICS的风险均高于社区对照,调整风险比分别为1.50和1.62。提示出院过渡期应加强用药核对。

要点

  • 住院COPD患者出院后长效吸入药物无意停药风险显著高于未住院者
  • LAMA与LABA-ICS两类药物停药风险均升高,调整风险比分别为1.50和1.62
  • 应聚焦出院安全过渡与患者用药核对以减少无意停药

核心结论

  • 在高依从性COPD患者中,住院与长效吸入药物停药风险升高相关。
  • 研究结果提示依从性较差的患者中停药问题可能更大,需在前瞻性队列中确认与量化。
  • 质量改进应聚焦安全过渡和出院后患者用药核对。

研究设计与样本

  • 回顾性队列研究,使用加拿大安大略省2004至2016年健康行政数据。
  • 纳入年龄≥66岁、连续≥1年取LAMA或LABA-ICS处方的COPD成人。
  • 采用对数二项回归模型评估各药物队列住院后停药风险。

主要发现

  • 研究纳入27,613次住院出院,发生停药1,466次。
  • 78,953例连续使用LAMA或LABA-ICS的COPD患者中,住院者停药风险高于社区者。
  • LAMA调整风险比1.50(95%CI 1.34-1.67;P<.001),LABA-ICS调整风险比1.62(95%CI 1.39-1.90;P<.001)。
  • LAMA粗停药率住院组5.2%、社区组3.3%;LABA-ICS住院组5.5%、社区组3.1%。

临床怎么用

  • 对住院COPD患者出院时应核对并重启既往长效吸入药物,减少无意停药。
  • 将出院用药核对纳入质量改进流程,关注高依从性患者的药物延续性。

局限性

  • 为观察性研究,仅基于健康行政数据,可能存在未测量混杂。
  • 研究人群为高度依从的老年患者,结果外推至依从性一般者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients admitted to the hospital with COPD are commonly managed with inhaled short-acting bronchodilators, sometimes in lieu of the long-acting bronchodilators they take as outpatients. If held on admission, these long-acting inhalers should be re-initiated upon discharge; however, health-care transitions sometimes result in unintentional discontinuation. RESEARCH QUESTION: What is the risk of unintentional discontinuation of long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist and inhaled corticosteroid (LABA-ICS) combination medications following hospital discharge in older adults with COPD? STUDY DESIGN AND METHODS: A retrospective cohort study was conducted by using health administrative data from 2004 to 2016 from Ontario, Canada. Adults with COPD aged ≥ 66 years who had filled prescriptions for a LAMA or LABA-ICS continuously for ≥ 1 year were included. Log-binomial regression models were used to determine risk of medication discontinuation following hospitalization in each medication cohort. RESULTS: Of the 27,613 hospitalization discharges included in this study, medications were discontinued 1,466 times. Among 78,953 patients with COPD continuously taking a LAMA or LABA-ICS, those hospitalized had a higher risk of having medications being discontinued than those who remained in the community (adjusted risk ratios of 1.50 [95% CI, 1.34-1.67; P < .001] and 1.62 [95% CI, 1.39, 1.90; P < .001] for LAMA and LABA-ICS, respectively). Crude rates of discontinuation for people taking LAMAs were 5.2% in the hospitalization group and 3.3% in the community group; for people taking LABA-ICS, these rates were 5.5% in the hospitalization group and 3.1% in the community group. INTERPRETATION: In an observational study of highly compliant patients with COPD, hospitalization was associated with an increased risk of long-acting inhaler discontinuation. These Results suggest a likely larger discontinuation problem among less adherent patients and should be confirmed and quantified in a prospective cohort of patients with COPD and average compliance. Quality improvement efforts should focus on safe transitions and patient medication reconciliation following discharge.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Gershon AS, McGihon RE, Thiruchelvam D, et al. Medication Discontinuation in Adults With COPD Discharged From the Hospital: A Population-Based Cohort Study. Chest. 2020. PMID: 33011204. doi:10.1016/j.chest.2020.09.254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。